June 12, 2023 09:53 AM EDT

Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech

Kyle LaHucik

Senior Reporter

An early-stage China biotech hopes to break into the GLP-1 race for obesity and diabetes as heavyweights dominate the field, with Novo Nordisk already …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Ec­co­gene nabs $25M Se­ries B for GLP-1 and a NASH drug can­di­date, as com­peti­tors lap the Chi­na biotech

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech